Ruxolitinib Cream and Standard Therapies for Vitiligo: A 2026 Systematic Review of Approved and Guideline-Recommended Treatments
View StudyPlain-Language Summary
A 2026 PRISMA-based systematic review in the Journal of Dermatological Treatment examined every approved and guideline-recommended treatment for adult vitiligo, with special attention to ruxolitinib 1.5% cream, the only therapy specifically approved for the condition. Ruxolitinib cream outperformed vehicle in Phase II and III randomized trials on facial and total Vitiligo Area Scoring Index outcomes, while established therapies such as topical corticosteroids, calcineurin inhibitors, and narrowband UVB phototherapy remain effective choices for localized disease. The review concludes that treatment selection should be individualized to each patient's disease activity, body area affected, and personal preferences.
Abstract
Vitiligo is a chronic autoimmune depigmenting disorder in which autoreactive CD8+ T cells destroy melanocytes through IFN-gamma/JAK-STAT signaling, causing characteristic white patches on the skin that can profoundly affect quality of life. In 2022, ruxolitinib 1.5% cream became the first therapy specifically approved by the FDA for nonsegmental vitiligo in patients 12 years and older, marking a pivotal shift toward targeted JAK1/2 inhibition. Clinical guidelines also endorse a range of off-label standard therapies including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), narrowband ultraviolet B (NB-UVB) phototherapy, targeted 308-nm excimer devices, and selected systemic off-label regimens, but the comparative evidence across these treatments had not been comprehensively synthesized since the approval of ruxolitinib cream.
This review used a PRISMA-based approach to identify English-language articles published between 2000 and 2025 evaluating approved and guideline-recommended treatments for adult vitiligo. Primary outcomes were changes in Facial Vitiligo Area Scoring Index (F-VASI) and Total Vitiligo Area Scoring Index (T-VASI). Secondary outcomes included quality of life and safety. Risk of bias was assessed using the RoB 2 tool for randomized controlled trials and the ROBINS-I tool for non-randomized studies.
Ruxolitinib 1.5% cream demonstrated superior F-VASI responses compared with vehicle across Phase II and III randomized controlled trials, confirming it as the most robustly evidence-backed topical monotherapy for repigmentation in nonsegmental vitiligo. Potent or very potent topical corticosteroids, topical calcineurin inhibitors, NB-UVB phototherapy, and targeted 308-nm excimer devices showed efficacy in localized disease. Systemic regimens including oral JAK inhibitors and oral minipulse corticosteroids demonstrated benefit in selected clinical scenarios, particularly active or widespread disease, though supporting evidence was more heterogeneous. The authors conclude that individualized treatment selection based on disease activity, extent, anatomical site, and patient preferences is essential, and that ruxolitinib cream represents the current evidence standard for topical therapy in adult vitiligo.